がん薬物療法におけるポジトロンCT の役割
スポンサーリンク
概要
- 論文の詳細を見る
Abstract : It is the most important to evaluate the efficacy of anti-cancer agents rapidly in planning the treatment for the individual patient. The development of positron emission tomography (PET) has made it possible to study the metabolism of cancer tissues visually and evaluate the efficacy of cancer chemotherapy more rapidly and exactly than morphological examinations. 2-deoxy-2-[~18 F]fluoro-D-glucose (FDG) is a tracer for glucose metabolism and widely used in cancer diagnosis. Some reports showed that FDG was very useful for the early evaluation of cancer chemotherapy and the prediction of prognosis in patients with breast cancer, lymphoma, colonic cancer and esophageal cancer. From this point of view, tracers for nucleic and amino acid metabolisms are also promising. PET will play the more and more important role on the evaluation of efficacy for cancer chemotherapy. Key words : cancer chemotherapy, Positron emission tomography (PET), 2-deoxy-2-[~18 F]fluoro-D-glucose (FDG), evaluation of the efficacy for cancer chemotherapy
- 山形大学の論文
- 2008-02-15
著者
関連論文
- 肝癌・腎癌
- がん薬物療法におけるポジトロンCT の役割
- がん薬物療法におけるPETの役割 (特集 PET 癌イメージングの現在と今後の展開) -- (癌代謝イメージング--FDGの治療応用へ)
- がん薬物療法におけるPETの役割
- 低用量ネダプラチン・5FU併用放射線治療が著効した, 重度肝障害をともない全身状態不良の肝転移を有する食道癌の1例